Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic...
26 KB (2,389 words) - 05:48, 7 April 2024
Bcl-2 (section Venetoclax (ABT-199))
selective inhibitor venetoclax (ABT-199), which inhibits Bcl-2, but not Bcl-xL or Bcl-w. Clinical trials studied the effects of venetoclax, a BH3-mimetic drug...
41 KB (4,868 words) - 19:15, 19 May 2024
juvenile myelomonocytic leukemia. The combination of azacitidine and venetoclax is also approved for AML. Azacitidine is a chemical analogue of the nucleoside...
20 KB (1,915 words) - 00:12, 31 March 2024
to be one of the most up-regulated (i.e. overactive) genes in BPDCN. Venetoclax inhibits the apoptosis-inhibiting action of BCL-2 and proved active in...
22 KB (2,609 words) - 23:55, 3 January 2024
(i.e. DH/THL). RO6870810, another BET inhibitor, in combination with Venetoclax, an inhibitor of the Bcl-2 protein, is likewise in a phase I clinical...
69 KB (8,143 words) - 18:36, 22 January 2024
about 15-20% of multiple myeloma patients) may particularly benefit from Venetoclax therapy (which is FDA approved for other blood cancers but not yet available...
127 KB (13,052 words) - 10:10, 8 May 2024
the aim of not harming normal cells. Targeted drugs used in CLL include venetoclax (a Bcl-2 inhibitor), ibrutinib and acalabrutinib (Bruton's tyrosine kinase...
72 KB (7,560 words) - 17:11, 27 April 2024
biomarker Senotherapy Sirtuin-activating compound Unity Biotechnology Venetoclax YPEL3 § Cellular senescence Childs BG, Durik M, Baker DJ, van Deursen...
26 KB (2,013 words) - 05:15, 16 May 2024
Pharmaceutical drugs Humira (adalimumab) Imbruvica (ibrutinib) Venclexta (venetoclax) Zinbryta (daclizumab) Kaletra (lopinavir) Norvir (ritonavir) Mavyret/Maviret...
39 KB (3,327 words) - 10:40, 11 May 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
31 KB (2,940 words) - 06:07, 28 February 2024
Penicillamine Trimethoprim/sulfamethoxazole Clozapine Valproate Vaccination Venetoclax Severe bacterial infections, especially in people with underlying hematological...
33 KB (3,338 words) - 23:01, 16 May 2024
(paclitaxel, docetaxel, gemcitabine, and irinotecan), olaparib, erlotinib, venetoclax, and rituximab in advanced hematological malignancies (in both pediatric...
13 KB (1,219 words) - 16:58, 5 January 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
34 KB (3,112 words) - 09:16, 21 April 2024
tofacitinib ALK inhibitors, e.g. crizotinib Bcl-2 inhibitors (e.g. FDA approved venetoclax, obatoclax in clinical trials, navitoclax, and gossypol. PARP inhibitors...
20 KB (2,197 words) - 05:50, 29 November 2023
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
13 KB (850 words) - 06:46, 10 March 2024
Midostaurin Nintedanib Pazopanib Pemigatinib Pexidartinib Quizartinib Regorafenib Ripretinib Sorafenib Sunitinib Tebentafusp Tepotinib Vandetanib Venetoclax...
12 KB (741 words) - 18:39, 6 May 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
31 KB (2,816 words) - 15:19, 16 May 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
19 KB (1,681 words) - 07:11, 15 March 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
90 KB (9,943 words) - 09:46, 14 May 2024
(alectinib): Treatment for non-small cell lung cancer (NSCLC). 2016: Venclexta (venetoclax): Treatment for patients with chronic lymphocytic leukemia (CLL) who have...
37 KB (3,361 words) - 11:12, 21 May 2024
the compound was assigned the international nonproprietary name (INN) venetoclax. Similarly, other compounds may be given a USAN or BAN for example. Finally...
18 KB (1,656 words) - 12:20, 31 March 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
60 KB (6,032 words) - 04:21, 7 February 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
5 KB (313 words) - 21:41, 30 March 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
12 KB (1,052 words) - 10:08, 29 January 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
20 KB (1,806 words) - 04:05, 18 May 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
13 KB (1,472 words) - 14:48, 9 January 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
31 KB (2,770 words) - 04:10, 13 February 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
23 KB (1,753 words) - 03:22, 20 April 2024
Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
12 KB (1,314 words) - 18:29, 29 April 2024
myeloid leukemia cell line made the cells resistant to the BCL2 inhibitor Venetoclax, further supporting a role in cancer predisposition. Additional roles...
4 KB (473 words) - 11:43, 30 September 2023